



**HAL**  
open science

## CSF concentration of cefotaxime in adult patients with pneumococcal meningitis: a multicentre retrospective study

Paul Le Turnier, Najoua El Helali, Romain Guilhaumou, Benoit Pilmis, Matthieu Revest, Lionel Velly, Anne-Gaëlle Leroy, Xavier Duval, Florian Lemaitre, Matthieu Grégoire, et al.

### ► To cite this version:

Paul Le Turnier, Najoua El Helali, Romain Guilhaumou, Benoit Pilmis, Matthieu Revest, et al.. CSF concentration of cefotaxime in adult patients with pneumococcal meningitis: a multicentre retrospective study. *Journal of Antimicrobial Chemotherapy*, 2021, 76 (9), p. 2352-2355. 10.1093/jac/dkab191 . hal-03281931

**HAL Id: hal-03281931**

**<https://hal.science/hal-03281931>**

Submitted on 12 Jul 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

1 **TITLE PAGE - Brief Report**

2

3 **Title:**

CSF concentration of cefotaxime in adult patients with pneumococcal meningitis: a multicentre retrospective study

4

5

6

7 **Authors**

8 Paul LE TURNIER<sup>1\*</sup>, Najoua EL HELALI<sup>2</sup>, Romain GUILHAUMOU<sup>3</sup>, Benoit PILMIS<sup>4</sup>, Matthieu  
9 REVEST<sup>5</sup>, Lionel VELLY<sup>6</sup>, Anne-Gaëlle LEROY<sup>7</sup>, Xavier DUVAL<sup>8</sup>, Florian LEMAITRE<sup>9</sup>, Matthieu  
10 GREGOIRE<sup>10</sup> on behalf of the DIFCEFO study group†

11 <sup>1</sup> Department of Infectious Diseases, Nantes University Hospital, Nantes, France - INSERM CIC 1413,  
12 Nantes University Hospital, Nantes, France

13 <sup>2</sup> Plateforme de Dosages des Anti-infectieux, Groupe Hospitalier Paris Saint-Joseph, Paris, France

14 <sup>3</sup> Aix Marseille Univ, Department of Clinical Pharmacology and Pharmacovigilance CIC-CPCET,  
15 University Hospital Timone - Institut de neurosciences des systèmes, Inserm UMR 1106, Marseille,  
16 France

17 <sup>4</sup> Equipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France -  
18 Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France

19 <sup>5</sup> Infectious Diseases and Intensive Care Unit, Rennes University Hospital, Rennes, France - University of  
20 Rennes, Centre d'Investigation Clinique 1414, INSERM, Bacterial Regulatory RNAS and Medicine,  
21 Unité Mixte de Recherche 1230, Rennes, France

22 <sup>6</sup> Aix Marseille Univ, Department of Anaesthesiology and Critical Care Medicine, University Hospital  
23 Timone - CNRS, INT, Inst Neurosci Timone, UMR7289, Marseille, France

24 <sup>7</sup> Department of Microbiology, Nantes University Hospital, Nantes, France

25 <sup>8</sup> Paris University, IAME, INSERM, Paris, France - Inserm Clinical Investigation Centre 1425, Paris,  
26 France - Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris,  
27 France

28 <sup>9</sup> Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et  
29 travail), Rennes, France - UMR\_S 1085, F- INSERM, Centre d'Investigation Clinique, CIC 1414,  
30 Rennes, France

31 <sup>10</sup> Clinical Pharmacology Laboratory Department Nantes University Hospital, Nantes, France - UMR  
32 INSERM 1235, The enteric nervous system in gut and brain disorders, University of Nantes, Nantes,  
33 France

34 †Members are listed in the Acknowledgements section

35 \*Corresponding author

36

37 **Corresponding author**

38 Paul Le Turnier. Address : Department of Infectious and Tropical diseases, Nantes University Hospital, 1  
39 place Alexis Ricordeau 44093, Nantes, France. International phone number/fax : +33 2 40 08 33 47/+33 2  
40 40 08 33 30. E-mail : [paul.leturnier@gmail.com](mailto:paul.leturnier@gmail.com)

41

42 **Running title**

43 Cefotaxime in adult pneumococcal meningitis CSF

44 **Abstract**

45 **Background and objectives:** Pneumococcal meningitis is a devastating disease that requires adequate  
46 meningeal antibiotic penetration to limit the mortality. Despite a large usage in this indication, data about  
47 CSF concentration of cefotaxime during pneumococcal meningitis in adults are scarce. Therefore we  
48 aimed to describe the CSF concentration obtained after high-dose cefotaxime administration in adult  
49 patients treated for *Streptococcus pneumoniae* meningitis.

50 **Patients and methods:** In this multicentre, observational, retrospective study, cases of adult patients with  
51 *S. pneumoniae* meningitis hospitalized between January 2013 and October 2019 for whom cefotaxime  
52 concentration was measured in CSF were reviewed.

53 **Results:** Cefotaxime concentration was analysed in 44 CSF samples collected among 31 patients...  
54 Median (IQR) age was 61 years (52;69). Dexamethasone was administered in 27 subjects. Median (IQR)  
55 cefotaxime daily dosage was 15 g (12;19) corresponding to 200 mg/kg (150;280). CSF samples were  
56 collected 5 days after cefotaxime initiation roughly. Median (IQR, range) cefotaxime CSF concentration  
57 was 10.3 mg/L (4.8;19.3, 1.2-43.4). Median (range) MIC of *Streptococcus pneumoniae* was 0.25 mg/L  
58 (0.008-1) (n=22). The median (IQR, range) CSF/MIC ratio was 38 (12;146, 4-1844). Twenty-five CSF  
59 concentrations (81 %) were above 10 times the MIC. Cefotaxime was discontinued in 2 patients for  
60 toxicity. In-hospital mortality rate was 29%.

61 **Conclusions:** Adult patients with pneumococcal meningitis treated with high dose of cefotaxime (200  
62 mg/kg/day) had elevated CSF concentrations with satisfying pharmacokinetics/pharmacodynamics  
63 parameters and tolerability profile. This study brings reassuring pharmacological data regarding the use of  
64 high dose cefotaxime monotherapy for treating pneumococcal meningitis with susceptible strains to  
65 cefotaxime.

66

67 **TEXT (1217 words)**

## 68 **Introduction**

69 *Streptococcus pneumoniae* meningitis is a devastating disease with the highest morbidity and mortality  
70 among community-acquired bacterial meningitis. <sup>1</sup> Cefotaxime is a third-generation cephalosporin (3GC)  
71 widely recommended for the treatment of pneumococcal meningitis. French guidelines for management  
72 of acute bacterial meningitis recommend dosage of cefotaxime to be weight-based without any upper  
73 limit whereas international guidelines recommend a maximum daily dosage of 12 g. <sup>2-4</sup> The adequacy  
74 between antibiotic penetration in CSF and antibiotic susceptibility of *Streptococcus pneumoniae* is a  
75 cornerstone to achieve satisfying pharmacokinetics/pharmacodynamics (PK-PD) targets in this lethal  
76 disease. The increasing incidence of *Streptococcus pneumoniae* isolates with reduced susceptibility to  
77 3GC is therefore a matter of concern. <sup>5</sup> Given these epidemiological changes, data about cefotaxime  
78 penetration in CSF might offer relevant information. <sup>6</sup> However, very limited data exist about CSF  
79 penetration of cefotaxime when meningeal dose are used in adults treated for pneumococcal meningitis.  
80 We aimed to describe the CSF penetration of cefotaxime in adult patients treated for *S. pneumoniae*  
81 meningitis.

## 82 **Patients and methods**

83 We conducted a multicentre, observational, retrospective study. Adult patients hospitalized between  
84 January 2013 and October 2019 for whom cefotaxime concentration was measured in CSF as part of the  
85 routine care were identified in the participating centres and among the participants of the COMBAT  
86 cohort (NCT02916732). Among them, individuals treated for proven pneumococcal meningitis, with  
87 either positive CSF culture or CSF PCR assay for *Streptococcus pneumoniae*, were included. Medical  
88 charts were retrospectively reviewed to collect clinical, pharmacological and microbiological data. CSF  
89 parameters were reported at the time of cefotaxime concentration measurements in CSF. Concomitant  
90 cefotaxime plasma concentrations (same day) were collected when available. All CSF concentrations  
91 were measured within 48h following CSF sampling and were systematically stored at -80°C if they were

92 not immediately performed. Antibiotic concentrations were measured in CSF and plasma using a liquid-  
93 chromatography coupled with mass-spectrometry or diode-array detector validated assay. Limit of  
94 quantitation was 1 mg/L. A steady-state plasma concentration was defined by a cefotaxime concentration  
95 measured at least 24 hours after treatment initiation. Plasma concentrations were considered as trough  
96 levels when continuous infusion was used or when discontinued infusion was used and plasma samples  
97 collected just before infusion.

98 Cefotaxime MIC were determined using an Etest strips or Vitek 2 automated system (bioMérieux,  
99 France) depending on usual practices of the different centres and according to the European Committee  
100 on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The study received ethical approval from  
101 the Research Ethics Committee on Infectious and Tropical Diseases (CERMIT2019-0706,  
102 IRB00011642). Participants were informed of the study in accordance with French legal standards.

103 A Wilcoxon rank sum test was used to compare the cefotaxime CSF levels between patients with and  
104 without dexamethasone with a significance level of 0.05.

## 105 **Results**

### 106 *Study population*

107 In total, 31 individuals were included. Their characteristics are reported in **Table 1**. Median (IQR) age  
108 was 61 years (52;69). Dexamethasone was administered in 27 subjects (87 %). Median (IQR) cefotaxime  
109 daily dosage was 15 g (12;19) corresponding to 200 mg/kg (150;280). Sixteen out of 28 patients received  
110 cefotaxime by continuous intravenous infusion (3 missing data).

### 111 *Pharmacokinetics-pharmacodynamics analysis*

112 Forty-four CSF concentrations (from 1 to 4 per patient) and 28 plasma concentrations (from 0 to 4 per  
113 patient) were measured. The median (IQR) time between cefotaxime initiation and CSF sampling was  
114 121 hours (78-194), all above 24 hours (2 missing data). For patients who did not receive continuous  
115 infusion, the median (IQR) time between cefotaxime preceding infusion and CSF sampling was 3.3 (1.5-

116 5.3) hours. Median (IQR, range) CSF concentration was 10.3 mg/L (4.8;19.3, 1.2-43.4) (see **Table 1**).  
117 Median (IQR) plasma concentration was 60.5 mg/L (31.3-81.7). Plasma concentrations were trough levels  
118 in 75% (21/28) of patients. For paired CSF and plasma cefotaxime measurements (n=28 paired samples),  
119 the median (IQR) calculated CSF/plasma ratio was 21.6 % (8.6-28.5). The cefotaxime MIC of *S.*  
120 *pneumoniae* was reported for 22 (71%) subjects. Median (IQR, range) MIC was 0.25 mg/L (0.036;0.5,  
121 0.008-1). Based on the cefotaxime MIC of each patient's pneumococcal strain the median (IQR, range)  
122 CSF/MIC ratio was 38 (12-146, 4-1844) (n=31 CSF samples). Twenty-five CSF concentrations (81 %)  
123 were above 10 times the corresponding MIC. CSF cefotaxime levels did not differ between  
124 dexamethasone- and non-dexamethasone-treated patients (p=0.59). Considering the weight-based daily  
125 dosage and the associated CSF concentration, 6 patients received less than 150 mg/kg/day (n=9 samples),  
126 6 between 150 and 199 mg/kg/day (n=8 samples), 11 between 200 and 280 mg/kg/day (n=13 samples), 6  
127 above 280 mg/kg/day (n=10) with a median (IQR) CSF concentration of 7.5 mg/L (1.2;29.3), 10.3 mg/L  
128 (2.2;15.4), 5.4 mg/L (1.6;23.8), and 18.3 mg/L (3.0;43.4) respectively (see **Table 2**).

### 129 *Clinical outcomes*

130 Cefotaxime was discontinued because of toxicity in 2 patients (8.0 %, 6 missing data). One with acute  
131 kidney injury experienced a neurological degradation with electroencephalogram abnormalities while  
132 having elevated cefotaxime concentrations in CSF (19.3 mg/L) and plasma (254.9 mg/L). The details on  
133 toxicity were not available for the other patient. In hospital mortality rate was 29 % (9/31).

### 134 **Discussion**

135 Previous studies assessing CSF penetration of cefotaxime were mostly done in children and revealed  
136 lower concentrations than in this study,<sup>7</sup> or variable concentrations similarly to those observed here.<sup>8</sup>  
137 Interestingly, a previous PK/PD modelling study suggested that cefotaxime dosages of 4g/6h would be  
138 sufficient to achieve CSF levels above the MIC for 90% of time, even for pneumococcal strains with an  
139 MIC of 2, which appear close to the results observed in the current study.<sup>9</sup>

140 The IDSA and the ESCMID guidelines for acute bacterial meningitis treatment in adults recommend a  
141 cefotaxime daily dosage from 8 to 12 g, in association with vancomycin or rifampicin when reduced  
142 susceptibility to penicillin is suspected, which is the case in France.<sup>3,4</sup> Meanwhile, French guidelines  
143 promote a monotherapy of cefotaxime with a dose-weighted adjustment without any upper limit dosage  
144 and recommend dosages based on cefotaxime susceptibility which range from 200 mg/kg when MIC is  
145 below 0.5 mg/L (susceptible strain) to 300 mg/kg when MIC is between 0.5 mg/L and 2 mg/L  
146 (intermediate strain) or unknown.<sup>2</sup>

147 Recently, Mizrahi and coll. reported a case of therapeutic failure in a patient with 3GC-intermediate  
148 *Streptococcus pneumoniae* meningitis.<sup>10</sup> After several days of ceftriaxone monotherapy the patient's state  
149 worsened and repeated CSF culture revealed a 3GC-resistant *Streptococcus pneumoniae* isolate. This  
150 resistance emergence possibly occurred due to insufficient exposition of antibiotics.<sup>11</sup> Because a limited  
151 exposition to antibiotics can lead to resistant strain selection, it appears necessary to target CSF  
152 concentrations far above the MIC although the optimal CSF/MIC ratio target remains uncertain.<sup>12</sup>

153 In France, the incidence of pneumococcal meningitis with decreased 3GC susceptibility reached its lowest  
154 point in 2014 when 1.5% of strains were cefotaxime-intermediate and none resistant. Since then, this  
155 proportion increased relatively with 6.6% in 2017 with rare resistant strains (0.7%).<sup>13</sup> The  
156 pharmacological results of our study suggest that using high-dose cefotaxime (200 mg/kg) seems a  
157 reasonable option to treat cefotaxime-susceptible strains. Notably, the highest CSF concentrations  
158 observed in this cohort were found in patients receiving daily dosage above 280 mg/kg with a median of  
159 18 mg/L and were higher than previous reports in adults receiving meningeal dose of cefotaxime.<sup>14,15</sup>  
160 Those very high dosages corresponded approximately to the initial empirical dosage proposed by French  
161 guidelines and could be sufficient to treat even cefotaxime-intermediate strains.

162 The global satisfying tolerability of cefotaxime despite the high doses used in the study population is in  
163 accordance with previous reports of very high doses of other 3GC in patients treated for suspected CNS  
164 infections.<sup>16</sup>



165 The limitations of our study include: i) the retrospective design, ii) a small sample size, which prevents to  
166 analyse the factors associated with CSF cefotaxime penetration and patients' outcomes, iii) some missing  
167 data regarding the indication of CSF antibiotic dosing and the dosage of dexamethasone (although it is  
168 likely that the recommended dosage of 10 mg/q6h was administered), iv) a possible selection bias because  
169 repeated CSF analysis is not systematically recommended but only in case of elevated MIC or  
170 unfavourable outcome.<sup>2</sup>

171 High dose cefotaxime regimens (200 mg/kg) used in adults during pneumococcal meningitis lead to  
172 elevated CSF levels associated with satisfying PK-PD parameters in CSF. Despite its limitations this  
173 study brings reassuring pharmacological and clinical data regarding the use of high dose cefotaxime as  
174 recommended in France for treating pneumococcal meningitis with 3GC susceptible strains.

#### 175 **Authors' contributions**

176 Paul Le Turnier (Conceptualization, Methodology, Investigation, Data curation, Formal analysis,  
177 Visualization, Methodology, Writing – original draft), Najoua El Helali (Investigation, Writing – review  
178 and editing), Romain Guilhaumou (investigation), Benoit Pilmis (Investigation, Writing – review and  
179 editing), Lionel Jean Velly (Investigation) Matthieu Revest (Investigation), Anne Gaele Leroy  
180 (Methodology, Writing – original draft), Xavier Duval (Conceptualization, Investigation, Writing –  
181 review and editing), Florian Lemaitre (Investigation, Writing – review and editing), Matthieu Grégoire  
182 (Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing – original draft).

#### 183 **Acknowledgements**

184 Preliminary results of this study were presented as a poster at the 30th European Congress of Clinical  
185 Microbiology and Infectious Diseases, Paris, France, 2020 (Abstract 9506). We thank the clinicians,  
186 pharmacologists and microbiologists who contributed to the management of the study patients for their  
187 commitment to providing optimal patient care.

188 DIFCEFO study group: (Nantes University Hospital) Paul Le Turnier, Matthieu Gregoire, Anne-Gaëlle  
189 Leroy; (Saint-Joseph group) Najoua El-Helali, Benoît Pilmis; (Rennes University Hospital) Matthieu  
190 Revest, Florian Lemaitre; (Marseille University Hospital) Romain Guilhaumou, Lionel Velly (Quimper  
191 Hospital) Jean-Philippe Talarmin; (Amiens University Hospital) Jean-Luc Schmit, Youssef Bennis;  
192 (Nancy University Hospital) Alexandre Charmillon, Julien Scala-Bertola; (Strasbourg University  
193 Hospital) Joy Mootien; (Cochin University Hospital) Solen Kernéis; (Reims University Hospital) Firouze  
194 Bani-Sadr, Yohan Nguyen, Zoubir Djerada; (IAME, INSERM, Paris; COMBAT cohort) Xavier Duval.

### 195 **Funding**

196 The COMBAT cohort study was supported by the Assistance Publique Hopitaux de Paris, French  
197 Ministry of Health, Inserm, SPILF, and the Pfizer Pharmaceutical company, which also funded ORP. This  
198 ancillary study was carried out as part of our routine work.

### 199 **Transparency declarations**

200 None to declare

### 201 **References**

- 202 1. Tubiana S, Varon E, Biron C, *et al.* Community-acquired bacterial meningitis in adults: in-hospital  
203 prognosis, long-term disability and determinants of outcome in a multicentre prospective cohort. *Clin*  
204 *Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2020; **26**: 1192–200.
- 205 2. Hoen B, Varon E, de Debroucker T, *et al.* Management of acute community-acquired bacterial  
206 meningitis (excluding newborns). Long version with arguments. *Med Mal Infect* 2019; **49**: 405–41.
- 207 3. Tunkel AR, Hasbun R, Bhimraj A, *et al.* 2017 Infectious Diseases Society of America’s Clinical  
208 Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. *Clin Infect Dis* 2017; **64**:  
209 e34–65.
- 210 4. van de Beek D, Cabellos C, Dzupova O, *et al.* ESCMID guideline: diagnosis and treatment of acute  
211 bacterial meningitis. *Clin Microbiol Infect* 2016; **22**: S37–62.
- 212 5. Kaur R, Pham M, Yu KOA, *et al.* Rising Pneumococcal Antibiotic Resistance in the Post–13-Valent  
213 Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. *Clin Infect Dis*  
214 2021; **72**:797-805.

- 215 6. Gustafsson I, Löwdin E, Odenholt I, *et al.* Pharmacokinetic and pharmacodynamic parameters for  
216 antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. *Antimicrob Agents*  
217 *Chemother* 2001; **45**: 2436–40.
- 218 7. Doit C, Barre J, Cohen R, *et al.* Bactericidal activity against intermediately cephalosporin-resistant  
219 *Streptococcus pneumoniae* in cerebrospinal fluid of children with bacterial meningitis treated with high  
220 doses of cefotaxime and vancomycin. *Antimicrob Agents Chemother* 1997; **41**: 2050–2.
- 221 8. Goldwater PN. Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial  
222 meningitis in children. *Int J Antimicrob Agents* 2005; **26**: 408–11.
- 223 9. Dahyot-Fizelier C, Frasca D, Grégoire N, *et al.* Microdialysis Study of Cefotaxime Cerebral  
224 Distribution in Patients with Acute Brain Injury. *Antimicrob Agents Chemother* 2013; **57**: 2738–42.
- 225 10. Mizrahi A, Marvaud JC, Pilmis B, *et al.* Emergence of Ceftriaxone Resistance during a Case of  
226 Pneumococcal Meningitis with Fatal Evolution. *Antimicrob Agents Chemother* 2019; **64**: e01958-19,  
227 /aac/64/3/AAC.01958-19.atom.
- 228 11. Hasbun R. Case Commentary: Delayed Cerebral Vasculitis Associated with the Development of  
229 Ceftriaxone-Resistant Pneumococcal Meningitis. *Antimicrob Agents Chemother* 2020; **64**: e02251-19,  
230 /aac/64/3/AAC.02251-19.atom.
- 231 12. Täuber MG, Doroshov CA, Hackbarth CJ, *et al.* Antibacterial activity of beta-lactam antibiotics in  
232 experimental meningitis due to *Streptococcus pneumoniae*. *J Infect Dis* 1984; **149**: 568–74.
- 233 13. Varon 2018. *Rapport annuel d'activité du Centre National de Référence des Pneumocoques - Année*  
234 *d'exercice 2017*. <https://cnr-pneumo.com/docman/rapports/39-2018-epidemiologie-2017/file>.
- 235 14. Humbert G, Leroy A, Nair SR, *et al.* Concentrations of cefotaxime and the desacetyl metabolite in  
236 serum and CSF of patients with meningitis. *J Antimicrob Chemother* 1984; **13**: 487–94.
- 237 15. Peretti P, Sueri L, Tosi M, *et al.* Cefotaxime in the cerebrospinal fluid and serum in patients with  
238 purulent meningitis. *J Antimicrob Chemother* 1984; **14**: 117–23.
- 239 16. Le Turnier P, Navas D, Garot D, *et al.* Tolerability of high-dose ceftriaxone in CNS infections: a  
240 prospective multicentre cohort study. *J Antimicrob Chemother* 2019; **74**: 1078–85.

241

242

## 243 TABLES

244 Table 1: Description of study population's characteristics and outcomes, antibiotic therapy  
245 characteristics, CSF parameters and pharmacological results (n=31 patients)**Study population characteristics**

Age, years, median (IQR)	61 (52;69)
Weight, Kg, median (IQR) <sup>a</sup>	75.5 (60.7;90.2)
Glomerular filtration (CKD-EPI) at each CSF samples, mL/min/1.73 m <sup>2</sup> , median (IQR) <sup>b</sup>	91 (78;105.3)
Dexamethasone, n (%)	27 (87)
In-hospital mortality, n (%)	9 (29)
<i>S. pneumoniae</i> MIC, mg/L, median (min;Q1;Q3;max) <sup>c</sup>	0.25 (0.008;0.032;0.5;1)

**Characteristics of the cefotaxime therapy**

Daily dosage, g, median (IQR) <sup>d</sup>	15 (12;19)
Daily dosage, mg/Kg, median (IQR) <sup>e</sup>	200 (150;280)
Continuous infusion, n (%) <sup>f</sup>	16 (57)
Frequency in intermittent infusion, n/24h, median (IQR)	6 (4;6)
Discontinuation for toxicity, n (%) <sup>g</sup>	2 (8)

**CSF parameters in samples used for pharmacological measurements**

CSF samples with antibiotic dosing, n	44
---------------------------------------	----

CSF sampling via LP, n (%)	33 (75)
White blood cells/mm <sup>3</sup> , median (IQR) <sup>h</sup>	111 (32;565)
Protein g/L, median (IQR) <sup>i</sup>	2.2 (1.2;2.7)
Glucose mmol/L, median (IQR) <sup>j</sup>	3.28 (1.65;6.11)

### Pharmacological results of cefotaxime measurements

CSF concentration, mg/L, median (min;Q1;Q3;max)	
- All patients (n=44)	10.5 (1.2;4.9;19.3;43.4)
- Patients with dexamethasone (n= 33)	9.3 (1.6;4.5;15.4;39.1)
- Patients without dexamethasone (n=11)	12.3 (1.2;6.5;20.4;43.4)
Plasma concentration, mg/L, median (min;Q1;Q3;max) <sup>k</sup>	60.5 (13.5;31;81.7;254.9)
CSF/Plasma concentration ratio, %, median (min;Q1;Q3;max) <sup>k</sup>	21.6 (1.4;8.6;28.5;183.8)
CSF/MIC ratio, median (min;Q1;Q3;max) <sup>l</sup>	38 (4;12;146;1844)
CSF/MIC > 10, n (%) <sup>l</sup>	25 (81)

246 CTX, Cefotaxime; CKD-EPI, Chronic Kidney Disease EPIdemiology collaboration, LP, Lumbar  
 247 puncture; PK-PD, Pharmacokinetics-pharmacodynamics; min, minimum; Q1, first quartile; Q3, third  
 248 quartile; max, maximum.

249 <sup>a</sup>missing data: n=3/31; <sup>b</sup>creatinin clearance values were collected for each CSF sample, missing data:  
 250 n=4/44; <sup>c</sup>missing data: n=9/31; <sup>d</sup> missing data: n=1/44; <sup>e</sup> missing data: n=4/44; <sup>f</sup> missing data: n=3/31;

251 <sup>g</sup>missing data: n=6/31; <sup>h</sup>missing data: n=11/44; <sup>i</sup>missing data: n=12/44; <sup>j</sup>missing data: n=13/44; <sup>k</sup>missing  
 252 data: n=17/44; <sup>l</sup>missing data: n=14/44.

253 **Table 2. CSF concentrations of cefotaxime according to weight-based daily dosage (n=40 dosages, 4**  
 254 **missing data)**

Daily dosage (mg/kg/day)	<150	[150-199]	[200-280]	>280
Number of patients	6	6	11	6
Number of dosages	9	8	13	10
Time since CTX initiation, hours, median	120	144	96	193
Creatinin clearance, ml/min, median	51	77.5	86.0	96.5
Creatinin clearance < 30ml/min, n	4 (1 md)	0	1 (2 md)	0
CSF concentration, mg/L, median (range)	7.5 (1.2;29.3)	10.3 (2.2;15.4)	5.4 (1.6;23.8)	18.3 (3.0;43.4)

255 Md, missing data; CTX, Cefotaxime